Despite recent advances in chemotherapy, outcomes of patients with peritoneal metastases (PM) from gastric cancer are still very poor and standard treatment has not been established. Although oral S-1 appears to be effective for patients with PM, the effects of systemic chemotherapy are limited. Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) yield fewer benefits in patients with PM from gastric cancer than in patients with PM from other malignancies. In comparison, repeated intraperitoneal chemotherapy (RIPEC) with taxanes using an implantable peritoneal access port has a pharmacokinetic advantage for the control of peritoneal lesions and in combination with systemic chemotherapy can result in surprisingly long-term survival in patients with PM from gastric cancer.
| INTRODUCTION
Gastric cancer is the fifth most common malignancy worldwide, and the third leading cause of cancer-related deaths. 1 The peritoneum is the most frequent site of metastases and recurrences in patients with gastric cancer. 2, 3 Although various approaches have been attempted such as extended resections, combination chemotherapy, heated intraperitoneal chemotherapy and immunotherapy, the prognosis of patients with peritoneal metastases (PM) is still very poor and there is no established standard treatment.
In general, these patients are treated with systemic chemotherapy similar to patients with other distant metastases. Based on the results of Asian phase III trials, 4, 5 fluoropyrimidine plus platinum agents are considered to be the standard regimens for advanced or recurrent gastric cancer, although docetaxel or anthracyclines are combined to treat patients in Western countries. 6, 7 However, the efficacy of these regimens for patients with PM is still unclear. Patients with PM with massive ascites are often excluded from clinical trials because of their poor general condition. Although the survival of patients with PM is supposed to be worse compared to patients without PM from gastric cancer who received chemotherapy, 8 there are few clinical trials specifically targeting patients with PM, probably because of the lack of measurable disease.
Intraperitoneal (IP) infusion of anticancer drugs was intended to
enable an increased dose and time of exposure of intra-abdominal tumor cells to anticancer drugs with minimal systemic toxic effects.
In fact, IP administration has been shown to result in a higher drug concentration and longer half-life in the peritoneal cavity compared
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with intravenous administration, although this is affected by a variety of biophysical parameters, including molecular weight, charge and solubility. 9, 10 Hyperthermia has been shown to increase the ben- Cap, capecitabine; CDDP, cisplatin; FOLFOX-4, oxaliplatin, leucovorin and 5-fluorouracil; 5Fu, 5-fluorouracil; MST, median survival time; MTX, methotrexate; Nab-PTX, nanoparticle albumin-bound paclitaxel; OS, overall survival; PM, peritoneal metastases; PTX, paclitaxel; P1, P2, P3; phase I, II, III; R/S, retrospective study; -, not described.
aggressive approach has been carried out mainly in patients with pseudomyxoma, mesothelioma, ovarian and colorectal cancers, which suggested considerable efficacy for PM as a result of these malignancies. However, evidence for this strategy against PM from gastric cancer is relatively scarce because of the low frequency of this condition in Western countries. In Asia, HIPEC combined with modified surgery has been used to treat patients with gastric cancer in specialized centers for many years, but large-scale comparative studies have not been done, probably because of the high toxicity associated with these regimens. and a good response with negative cytology after HIPEC in patients with gastric cancer. 36 
| REPEATED INTRAPERITONEAL CHEMOTHERAPY USIN G TAXANES
The most significant shortcoming of HIPEC is that a single dose, even with hyperthermia, is not sufficient to allow the anticancer drugs to infiltrate into the deep portion of metastatic lesions on the peritoneal surfaces, and therefore multiple IP doses are needed to result in marked antitumor effects on the PM. Repeat IP infusion of anticancer drugs using an implantable port system was carried out over a decade ago. To treat patients with PM from gastric cancer, neoadjuvant MMC and CDDP were used. However, the clinical effects of those series were disappointing, probably because those drugs are readily absorbed into the systemic circulation and do not stay in the abdominal cavity for a long time. Indeed, pharmacokinetic studies have shown relatively low ratios using area under the curve analysis comparing peritoneal cavity levels to the systemic compartment after IP doasage of MMC or CDDP. 10, 37 Therefore, this approach has long been abandoned in clinical trials.
In this century, however, attention is again focused on repeated intraperitoneal chemotherapy (RIPEC) using taxanes ( Figure 1 ). Tax Based on these basic findings, RIPEC using PTX or DTX at normothermic conditions has been attempted for the treatment of patients with PM from gastric cancer mainly in Japan. In those studies, IP taxanes were combined with systemic chemotherapy as neoadjuvant intraperitoneal and systemic chemotherapy (NIPS) and the results were already summarized in a previous review. 41 As shown in Table 3 , this approach resulted in a MST of 15.1~24.6 months and 1-year survival of over 70%, [42] [43] [44] [45] [46] [47] [48] [49] which are considerably better than results with systemic chemotherapy or HIPEC.
In fact, second-look laparoscopy showed a drastic macroscopic change in the appearance of PM in many patients (Figure 2 ). The Determining the appropriate criteria and timing for conversion surgery is an important clinical subject for the future.
Another important advantage of RIPEC is relatively mild toxicity compared with HIPEC. According to one series, grade 3/4 neutropenia occurred in 21%~50% 42, [45] [46] [47] [48] and port-related complications such as infection, occlusion and reflux occurred in 20.6%. 54 However, non-hematological toxicities were relatively rare with no treatmentrelated deaths. It is notable that abdominal pain, which is often considered to be a dose-limiting toxicity in IPC, was rarely observed probably because of the low dose of IP taxanes.
Patients with only isolated tumor cells in the peritoneal cavity (P0CY1) also have dismal long-term outcomes and there is no established consensus to direct treatment. 55 As this strategy can cause remarkable shrinkage of macroscopic tumors, RIPEC can be expected to be more effective against P0CY1 cases. In fact, the cytology converted to be negative in 71%~97% of patients with PM, [42] [43] [44] [45] [46] [47] [48] which has never been achieved in other methods in previous reports.
Moreover, when used for P0CY1 cases, 1-year OS rate was 84.2%
with negative change of cytology in 94.7% patients. 56 This suggests that RIPEC with taxanes has the splendid power to control peritoneal micrometastases and thus may be a promising strategy for the prevention of peritoneal recurrence for gastric cancer with serosal exposure. 57 As pharmaceutical companies are not interested in clinical trials of drugs with an already expired patent, a reasonable drug-approval system needs to be established for the sake of patients with this dismal condition. 70 Although these are early results, this method may be another promising strategy for the treatment of PM.
| OTHER NOVEL INTRAPERITONEAL TREATMENTS
Cell-free and concentrated ascites reinfusion therapy (CART) was originally developed for patients with cirrhotic ascites, but is fairly effective for palliation in patients with massive ascites. After recent technological improvements, autologous ascites which contains a large number of proteins and nutrients, can be reinfused without severe toxicity, often resulting in a drastic improvement of the general condition of cachectic patients with PM. 71, 72 In fact, induction of CART enables patients with highly advanced PM and massive ascites to receive IPC with improved survival. 
